Abstract: A method and device are provided for determining an input voltage of a transformer of a local network station. The method includes measuring an input current of the transformer, an output current of the transformer, an output voltage of the transformer, and a phase angle between the output current and output voltage. The method also includes determining a translation ratio and an admittance of a cross-member of a p-equivalent circuit diagram of the transformer of the local network station using the measured input current, the measured output current, the measured output voltage and the phase angle between the output current and the output voltage. The method also includes determining the input voltage of the transformer of the local network station based on the determined translation ratio and the determined admittance of the cross-member of the p-equivalent circuit diagram.

Abstract: A Test Access Mechanism (TAM) architecture for facilitating testing of IP blocks integrated on a System on a Chip (SoC). The TAM architecture includes a Test Controller and one or more Test Wrappers that are integrated on the SoC proximate to IP blocks. Test data and commands corresponding to input from an external tester are packaged by the Test Controller and sent to the Test Wrappers via an interconnect fabric. The Test Wrappers employ interface with one or more test ports to provide test data, control, and/or stimulus signals to the IP block to facilitate circuit-level testing of the IP block. Test results for the circuit-level tests are returned to the Test Controller via the fabric. Test Wrappers may be configured to pass through interconnect signals, enabling functional testing of IP blocks to be facilitated via test packages and test results transmitted between the Test Controller and the IP blocks via the fabric.

Abstract: The method includes the steps of: storing a plurality of parameter sets; selecting one of the plurality of parameter sets as a test parameter set to be evaluated; measuring performance only for one batch job out of N (N is a positive integer) batch jobs constituting full set performance measurement for the test parameter set; and calculating an evaluation value on the basis of a difference between an integral of measurement values obtained until the performance has been measured for r (r is a positive integer smaller than N) batch jobs by using the test parameter set; and an integral of mean measurement values of the performance for the r batch jobs by using an optimal parameter set which is one of the parameter sets used in the performance evaluation having been performed; determining whether or not the evaluation value has deviated from a predetermined evaluation continuing range; and terminating the evaluation of the test parameter set on condition that it is determined that the evaluation value has deviat

Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

Abstract: The present invention provides processes for determining the molecular weight of glatiramer acetate and other copolymers using molecular weight markers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight. The molecular weight markers also optimally demonstrate biological activity similar to glatiramer acetate or corresponding copolymers and can be used for treating or preventing various immune diseases.

Abstract: Human serum paraoxonase enzyme and DNA (RNA) encoding such serum paraoxonase enzymes are disclosed. Also provided is the procedure for producing such polypeptides by recombinant techniques. Uses of such polypeptides include their use as an antidote for organophosphate poisoning and to prevent neuronal cell death.

Abstract: Pooled human plasma is processed by cold ethanol fractionation to produce purified immunoglobulin G antibodies for intravenous administration. Immunoglobulin A is an unwanted by-product since intravenous administration of immunoglobulin A-containing immunoglobulin G can cause life-threatening anaphylaxis in some people. The present invention is the topical application of immunoglobulin A coupled with J chain, and optionally coupled with secretory component in order to render the immunoglobulin A more physiologically active, for the prevention or treatment of ocular diseases including ocular immune deficiency and infections. Antigen-specific monoclonal immunoglobulin A may be used.